Macquarie Group LTD Ultragenyx Pharmaceutical Inc. Call Options Transaction History
Macquarie Group LTD
- $85.1 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RARE
# of Institutions
293Shares Held
88.2MCall Options Held
535KPut Options Held
198K-
Vanguard Group Inc Valley Forge, PA9.78MShares$493 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$282 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA5.35MShares$270 Million0.68% of portfolio
-
Wellington Management Group LLP Boston, MA4.56MShares$229 Million0.03% of portfolio
-
Rtw Investments, LP New York, NY3.26MShares$164 Million2.24% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $3.53B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...